Half-year Financial Report

AI SummaryClose X

BioPharma Credit PLC reported a return after finance costs and taxation of $50.4 million for the first half of 2026, with Net Asset Value per share decreasing slightly to $1.0148 from $1.0192 at the end of 2025, primarily due to a special dividend payment. The company made new commitments totaling $716.3 million during the period, including significant loans to Esperion, Idorsia, Mineralys, and Zenas, and also received loan repayments and sold notes, generating a $9.1 million gain from Cytokinetics note sales. Post-period, a new $45 million commitment was made to Kestra. The company repurchased 7.0 million shares under its Discount Control Mechanism, narrowing the discount to NAV from 10.1% to 6.0%.

Disclaimer*

UK 100